A status report on the use of subantimicrobial-dose doxycycline: A review of the biologic and antimicrobial effects of the tetracyclines

Cutis

Volumn 74, Issue 2, 2004, Pages 118-122

  Del Rosso, James Q ^a,b,c  

^a UNIVERSITY OF NEVADA   (United States)

^b Managed Care and Professional Affairs   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BENZOYL PEROXIDE; CLINDAMYCIN; DOXYCYCLINE; ERYTHROMYCIN; INTERLEUKIN 1; LINCOSAMIDE; MACROLIDE; METICILLIN; METRONIDAZOLE; MINOCYCLINE; PLACEBO; PSEUDOMONIC ACID; QUINOLONE; REACTIVE OXYGEN METABOLITE; TETRACYCLINE; TUMOR NECROSIS FACTOR ALPHA; VANCOMYCIN;

ACNE VULGARIS; ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; BODY WEIGHT; CELL MIGRATION; CLINICAL TRIAL; COAGULASE NEGATIVE STAPHYLOCOCCUS; COMMENSALISM; CORYNEBACTERIUM ACNES; DERMATITIS; DISEASE SEVERITY; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; LONGITUDINAL STUDY; LOW DRUG DOSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NEUTROPHIL; PERIODONTITIS; PRESCRIPTION; REVIEW; ROSACEA; STAPHYLOCOCCUS AUREUS; STATISTICAL SIGNIFICANCE; STREPTOCOCCUS PYOGENES; UNITED KINGDOM; UNITED STATES;

EID: 4444373178     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Del Rosso JQ. Systemic therapy for rosacea: focus on oral antibiotic therapy and safety. Cutis. 2000;66(suppl 4):7-13.
2. Bikowski JB. Subantimicrobial dose doxycycline for acne and rosacea. Skinmed. July/August 2003:1-12.
3. Maibach H. Second-generation tetracyclines, a dermatologic overview: clinical uses and pharmacology. Cutis. 1991;48:411-417.
4. Eady AH, Cove JH, Layton AM. Is antibiotic resistance in cutaneous propionibacteria clinically relevant?: implications of resistance for acne patients and prescribers. Am J Clin Dermatol. 2003;4:813-831.
5. Bikowski JB. Rosacea: a tiered approach to therapy. Cutis. 2000;66(suppl 4):3-6.
6. Meynadier J, Alirezai M. Systemic antibiotics for acne. Dermatology. 1998;196:135-139.
7. Webster GF, Leyden JJ, McGinley KJ, et al. Suppression of polymorphonuclear leukocyte chemotactic factor production in Propionibacterium acnes by subminimal inhibitory concentrations of tetracycline, ampicillin, minocycline and erythromycin. Antimicrob Agents Chemother. 1982;21:770-772.
8. Guay DRP. Treatment of bacterial skin and skin structure infections. Expert Opin Pharmacother. 2003;4:1259-1275.
9. FDA to require warning labels on antibiotics. Health Care Business Daily. February 6, 2003.
10. Eady EA. Bacterial resistance in acne. Dermatology. 1998;196:59-66.
11. Ferguson J. Recent trends in prescribing of antibiotics. Prescriber. 2001;12:59-62.
12. Crawford WW, Crawford IP, Stoughton RB, et al. Laboratory induction and clinical occurrence of combined clindamycin and erythromycin resistance in Corynebacterium acnes. J Invest Dermatol. 1979;72:187-190.
13. Guin JD, Huber DS, Gierlerak PL. Antibiotic susceptibility of comedonal Propionibacterium acnes. Acta Derm Venereol. 1979;59:552-554.
14. Cooper AJ. Systematic review of Propionibacterium acnes resistance to systemic antibiotics. Med J Aust. 1998;169:259-261.
15. Ross JI, Snelling AM, Carnegie E, et al. Antibiotic-resistant acne: lessons from Europe. Br J Dermatol. 2003;148:467-478.
16. Jones CF, Vyakrnam S, Eady EA, et al. Antibiotic resistant Propionibacteria and acne: crisis or conundrum [abstract]? J Invest Dermatol. 1997;108:381.
17. Coates P, Vyakrnam S, Eady EA, et al. Prevalence of antibiotic-resistant Propionibacteria on the skin of acne patients: 10-year surveillance data and a snapshot distribution study. Br J Dermatol. 2002;146:840-848.
18. Ross JI, Snelling AM, Eady EA, et al. Phenotypic and genotypic characterization of antibiotic-resistant Propionibacteruim acnes isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia. Br J Dermatol. 2001;144:339-346.
19. Leeming JP, Holland KT, Cunliffe WJ. The microbial ecology of inflamed acne vulgaris lesions. Br J Dermatol. 1988;118:203-208.
20. Levy RM, Huang EY, Roling D, et al. Effect of antibiotics on the oropharyngeal flora in patients with acne. Arch Dermatol. 2003;139:467-471.
21. Golub LM, Lee HM, Ryan ME, et al. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res. 1998;12:12-26.
22. Miyachi Y, Yoshioka A, Imamura S, et al. Effect of antibiotics on the generation of reactive oxygen species. J Invest Dermatol. 1986;86:449-453.
23. Skidmore R, Kovach R, Walker C, et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol. 2003;139:459-464.
24. Golub LM, Ciancio S, Rhamamamurthy NS, et al. Low-dose doxycycline therapy: effect on gingival and crevicular fluid collagenase activity in humans. J Periodontal Res. 1990;25:321-330.
25. Periostat [package insert]. Newton, Pa: CollaGenex Pharmaceuticals, Inc; 2003.
26. Sanchez J. Single-center, randomized, double-blind study of subantimicrobial-dose doxycycline and metronidazole 0.75% lotion for moderate rosacea. Paper presented at: Caribbean Dermatology Meeting; January 2003; San Juan, Puerto Rico.
27. Thomas J, Walker C, Bradshaw M. Long-term use of subantimicrobial-dose doxycycline does not lead to changes in antimicrobial susceptibility. J Periodontol. 2000;71:1472-1483.
28. Walker G, Thomas J, Nango S, et al. Long-term treatment with subantimicrobial dose doxycycline exerts no antibacterial effect on subgingival microflora associated with adult periodontitis. J Periodontol. 2000;71:1465-1471.
29. Walker G, Nango S, Lennon J, et al. Effect of subantimicrobial dose doxycycline (SDD) on intestinal and vaginal flora. Poster presented at: International Association of Dental Research; 2000; Alexandria, Va.